Purpose: To describe how and why internal medicine clerkship directors (CDs) use locally developed, faculty-written (LFW) examinations.
Method: In 2009, the Clerkship Directors in Internal Medicine conducted an annual, online, confidential survey of its 107 U.S. and Canadian institutional members, including questions about LFW examinations. Data were analyzed using descriptive statistics and coding of free text.
Results: Sixty-nine of 107 members (64.5%) responded. The National Board of Medical Examiners (NBME) examination was administered by 93% (63/68), LFW examinations were used by 33% (22/67), and both types were used by 22% (17/67)-compared with 85%, 36%, and 12% in 2005. LFW examinations were frequently created by the CD alone (9/22; 41%) and consisted of one test (12/22; 52.2%), but some schools gave two (6/22; 26.1%), three (2/22; 8.6%), or four or more (3/22; 13%). Multiple-choice examinations were most common (26/38; 68.4%), followed by short-answer (8/38; 21.1%) and essay (4/38; 10.5%). Most were graded using preestablished criteria; half required a minimum passing score (60% most common). LFW exams were most commonly 5% to 10% of the total grade. Only a minority of CDs reported having reliability estimates or a control group for their exams. Most (70%) reported using LFW exams to cover content felt to be underrepresented by the NBME.
Conclusions: Findings strongly suggest that a minority of internal medicine CDs use LFW examinations, mostly to measure achievement not assessed by the NBME. However, validity evidence is not consistently being gathered, which may limit judgments based on exam results.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ACM.0b013e318258351b | DOI Listing |
Discov Oncol
January 2025
Division of Hematology/Oncology, The University of Texas Health Sciences Center at Houston, McGovern Medical School, 6431 Fannin Street, MSB 5.216, Houston, TX, 77030, USA.
The established protocol for the management of acute myeloid leukemia (AML) has traditionally involved the administration of induction chemotherapy, followed by consolidation chemotherapy, and subsequent allogeneic stem cell transplantation for eligible patients. However, the prognosis for individuals with relapsed and refractory AML remains unfavorable. In response to the necessity for more efficacious therapeutic modalities, targeted immunotherapy has emerged as a promising advancement in AML treatment.
View Article and Find Full Text PDFKidney Int
January 2025
Laboratório de Fisiopatologia Renal (LIM 16), Nephrology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Universidade de São Paulo, São Paulo, Brazil. Electronic address:
In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Since then, new lines of evidence have been published related to evaluating disordered mineral metabolism and bone quality and turnover, identifying and inhibiting vascular calcification, targeting vitamin D levels, and regulating parathyroid hormone. For an in-depth consideration of the new insights, in October 2023, KDIGO held a Controversies Conference on CKD-MBD: Progress and Knowledge Gaps Toward Personalizing Care.
View Article and Find Full Text PDFCytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFJ Infect Dev Ctries
December 2024
Chest Dpt., Ahmed Maher Teaching Hospital, GOTHI, Cairo, Egypt.
Introduction: The present study aimed to explore the epidemiologic threats and factors associated with the coronavirus disease 2019 (COVID-19)-associated mucormycosis (CAM) epidemic that emerged in Egypt during the second COVID-19 wave. The study also aimed to explore the diagnostic features and the role of surgical interventions of CAM on the outcome of the disease in a central referral hospital.
Methodology: The study included 64 CAM patients from a referral hospital for CAM and a similar number of matched controls from COVID-19 patients who did not develop CAM.
J Infect Dev Ctries
December 2024
Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Introduction: The objective of this study was to assess the effectiveness of ivermectin and colchicine as treatment options for coronavirus disease 2019 (COVID-19).
Methodology: A three-arm randomized controlled clinical trial was conducted in the Triage Clinic of the family medicine department at Ain Shams University Hospitals on participants who had been diagnosed with moderate COVID-19. Patients aged < 18 years or > 65 years, with any co-morbidities, pregnant or lactating females, and those with mild or severe COVID-19 confirmed cases were excluded.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!